Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720798 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,067
- Enrollment target
NCT00720798: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00720798 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2,067 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (168% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720798, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,067 participants
- Enrollment target
Study Summary
This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.
Interventions
- DRUG Tocilizumab
- DRUG Non-steroidal anti-inflammatory drugs
- DRUG Disease-modifying anti-rheumatic drugs
- DRUG Oral corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,067 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT00720798 record still lists
NCT00720798 is an interventional study that assigns participants to a tested intervention. Its 2,067 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (168% higher).
The record links to 0 conditions, and to 4 interventions - of which Tocilizumab is the first listed.
NCT00720798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720798 about?
NCT00720798 is a clinical study titled "An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies". This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rhe...
What is the current status of trial NCT00720798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,067 participants. The study started on 2005-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00720798?
The interventions under investigation include: Tocilizumab (DRUG), Non-steroidal anti-inflammatory drugs (DRUG), Disease-modifying anti-rheumatic drugs (DRUG), Oral corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00720798?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720798's enrollment target sits among peer trials
2,067 99th of 2000 higher than 1,902 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia